Drug Approval | September 30, 2022
Lupin receives US FDA approval for Mirabegron Extended-Release tablets
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)